

BLAVATNIK STARTUPS

EpiTET Therapeutics



EpiTET's novel targets and molecular glue degrader approach has the potential to revolutionize the way a number of chronic inflammatory conditions are treated including endometriosis, metabolic dysfunction (MASH), and cancers, among other conditions. EpiTET's approach selectively eliminates pathogenic macrophages, the key drivers of chronic inflammation and disease micro-environment without suppressing overall immunity.



**YALE
VENTURES**



BLAVATNIK FUND
for Innovation at Yale

BLAVATNIK STARTUPS



KaryoVerse Therapeutics is a leading biotechnology company dedicated to the discovery and development of innovative cancer therapies. By targeting cancer aneuploidy, KaryoVerse's cutting-edge technologies aim to generate a new universe of therapeutics to fight this devastating disease.



**YALE
VENTURES**



BLAVATNIK FUND
for Innovation at Yale

BLAVATNIK STARTUPS



PanV, Inc., a biotechnology spun out of Yale's Iwasaki Laboratory, is developing pan-viral assets targeting diverse viruses. PanV antibodies specifically recognize unique host-derived modifications on the surface of the viral particles bringing a revolutionary solution for permanently addressing multiple types of viral infections including retroviruses, influenza, coronaviruses, and herpes viruses with a single therapeutic.



**YALE
VENTURES**



BLAVATNIK FUND
for Innovation at Yale

BLAVATNIK STARTUPS



*Stradefy
Biosciences*

Stradefy Biosciences is developing "Bioadhesive Drug Carriers" or BDC for targeted oncology use. The materials have been engineered for cellular bioadhesion and rapid uptake, increasing the therapeutic index of potent chemotherapies. With strong in vivo efficacy and a capital-efficient path to market, the team is advancing IND- enabling activities. Stradefy was co-founded by Mark Saltzman and Michal Girardi.




**YALE
VENTURES**



BLAVATNIK FUND
for Innovation at Yale

BLAVATNIK STARTUPS



RIGImmune

RIGImmune is developing innovative RNA therapeutics for direct delivery to the respiratory tract, utilizing proprietary NEEDM delivery platform for the benefit of patients with respiratory diseases of high unmet needs. RIG-101, RIGImmune's lead candidate, is advancing to the clinic in 2025, targeting the innate immune system through intranasal delivery to reduce the risk of severe asthma exacerbations caused by respiratory viruses. RIG-301, an inhaled NEEDM-formulated mRNA encoding wild type CFTR, delivers effectively to bronchial and alveolar cells to treat cystic fibrosis patients irrespective of their CFTR mutation.



**YALE
VENTURES**



BLAVATNIK FUND
for Innovation at Yale

BLAVATNIK STARTUPS

PLYTHERA

Plythera is focused on epiregulin inhibition as a novel approach to the treatment of systemic sclerosis and other fibrotic conditions. The company is currently raising Series A funding, led by Canaan and Cures Ventures.

Launched in 2023, Plythera is the first Yale spinout jointly supported by both Yale's Colton and Blavatnik accelerator funds.



**YALE
VENTURES**



BLAVATNIK FUND
for Innovation at Yale

BLAVATNIK STARTUPS



FerRx Bio

Therapies to Protect Vision

FerRx Bio, a Yale spinout, was co-founded by Mark Fields, MPH, PhD, Associate Professor of Ophthalmology and Lucian Del Priore MD, PhD, Professor of Ophthalmology at Yale School of Medicine. Following a favorable pre-IND meeting with the FDA, an experienced leadership team is ready to develop a prescription eye drop that uniquely targets the pathway central to the onset and progression of age-related macular degeneration (AMD) to prevent vision loss. There are currently no treatments available to prevent the progression of early/intermediate AMD.




**YALE
VENTURES**



BLAVATNIK FUND
for Innovation at Yale

BLAVATNIK STARTUPS



Most drugs are unable to reach targets in the central nervous system (CNS) due to their inability to cross the blood-brain barrier (BBB). D2B3 is determined to deliver a breakthrough in drug delivery (D2) across the BBB (B3). Having identified the BBB-master switch—a novel proprietary endothelial target—allows for delivery of various drugs in a plug-and-play fashion. D2B3 enables potent, off-patent therapies through access to the CNS as well as partners with other pharma companies around clinical stage assets addressing significant unmet needs in treating CNS diseases. The company is committed to overcoming the barrier that has been holding back CNS drug development for decades.



**YALE
VENTURES**



BLAVATNIK FUND
for Innovation at Yale